Alfred Health
Our Clinical Haematology service is affiliated with the laboratory and clinical research conducted by the Australian Centre for Blood Diseases (ACBD).
ACBD is a leading national and international blood diseases centre with recognised research, treatment, and educational programs for blood diseases. ACBD is affiliated with The Alfred, Monash University, Eastern Health and Southern Health.
Research is divided into two main groups:
For more information about our research groups, teaching and education programs, visit the Australian Centre for Blood Diseases.
Prof Harshal Nandurkar is the Program Director for Alfred Cancer, Director of Clinical Haematology and head of the Australian Centre for Blood Diseases.
Prof Andrew Spencer is the Head of our Malignant Haematology & Stem Cell Transplantation Service.
As the Director of Research, Stephen Jane is responsible to the Chief Executive for the strategic direction and governance of research at Alfred Health.
Our group focuses on several haematopoietic transcription factors recurrently mutated in acute lymphoblastic and myeloid leukemias (ALL and AML) and their role in tumour suppressor gene function.
Find out moreThe Wei and Guthridge research groups focus on the mechanisms by which cancer cells co-opt and coerce intracellular signalling pathways to promote deregulated cell survival, proliferation and growth.
Find out moreThe normal human immune system functions not only to remove infected cells but also to remove damaged or pre-cancerous cells.
Find out moreOur group uses transgenic mouse models and ES / iPS (embryonic stem / induced pluripotent stem) cell-based technologies to study cell fate and cellular transformation at the molecular level.
Find out moreOur group explores novel therapeutic approaches for multiple myeloma (MM) in preclinical and clinical studies.
Find out moreOur research focuses on the regulation of stem cells in haematopoietic and leukaemic cells through genetic and epigenetic studies.
Find out moreThe blood-brain barrier (BBB) becomes compromised in traumatic brain injury (TBI) and ischemic stroke patients, particularly after treatment with the thrombolytic agent tissue-type plasminogen activator (t-PA).
Find out moreWe are interested in how antibody targeted imaging agents and drug delivery vehicles can improve clinical diagnosis and therapy.
Find out moreArterial thrombosis underlies heart attacks and strokes and is the most common cause of death in Australia.
Find out moreOur group investigates platelet receptor levels in health and disease and how changes result in altered platelet function.
Find out moreOur research aims to identify pathways linking inflammation and thrombosis and to develop novel therapeutics targeted to specific vascular beds.
Find out more
Butera D, Passam F, Ju L, Cook KM, Woon H, Aponte-SantamarÃa C, Gardiner E, Davis AK, Murphy DA, Bronowska A, Luken BM, Baldauf C, Jackson S, Andrews R, Grâter F, Hogg PJ
(2018), Sci Adv, 4(2), eaaq1477
Samudra, A.N., Dwyer, K.M., Selan, C., Freddi, S., Murray-Segal, L., Nikpour, M., Hickey, M.J., Peter, K., Robson, S.C., Sashindranath, M., Cowan, P.J., Nandurkar, H.H.
(2018), J Autoimmun, 131-138
Besford, Quinn A.; Ju, Yi; Wang, Ting Yi; Yun, Gyeongwon; Cherepanov, Pavel V.; Hagemeyer, Christoph E.; Cavalieri, Francesca; Caruso, Frank
(2018), Small, 14(39), 1802342
Researchers are a step closer to offering older patients with an aggressive blood cancer, acute myeloid leukaemia (AML), a new less-toxic treatment option.
A complex surgery to remove chronic blood clots from arteries in the lungs is giving Australians and New Zealanders a second chance.
The Alfred and Monash University are set to establish Australia’s first dedicated blood cancer research centre, thanks to a $1.2 million grant from the Australian Cancer Research Foundation (ACRF).